Table 1.
STOML2 expression and clinicopathological features of HNSCC
| Clinicopathological Features | PSMD14 expression | Total | P value | |
|---|---|---|---|---|
|
| ||||
| Low | High | |||
| Overall | 46 (50.5%) | 45 (49.5%) | 91 | |
| Gender | ||||
| Male | 24 (42.9%) | 32 (57.1%) | 56 | 0.063 |
| Female | 22 (62.9%) | 13 (37.1%) | 35 | |
| Age | ||||
| ≤45 | 9 (64.3%) | 5 (35.7%) | 14 | 0.264 |
| >45 | 37 (48.1%) | 40 (51.9%) | 77 | |
| T stage | ||||
| T1-T2 | 31 (66%) | 16 (34%) | 47 | 0.003* |
| T3-T4 | 15 (34.9%) | 28 (65.1%) | 43 | |
| LN metastasis | ||||
| N0 | 29 (64.4%) | 16 (35.6%) | 45 | 0.009* |
| N1+N2+N3 | 17 (37%) | 29 (63%) | 46 | |
| Recurrence | ||||
| No | 37 (57.8%) | 27 (42.2%) | 64 | 0.033* |
| Yes | 9 (33.3%) | 18 (66.7%) | 27 | |
NOTE: The result was analyzed by the Pearson X2 test. P values with significance were shown with an asterisk.
*
P<0.05.